Gary Sinclair

1.6k total citations · 1 hit paper
20 papers, 918 citations indexed

About

Gary Sinclair is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Gary Sinclair has authored 20 papers receiving a total of 918 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Infectious Diseases, 9 papers in Virology and 5 papers in Epidemiology. Recurrent topics in Gary Sinclair's work include HIV Research and Treatment (9 papers), HIV/AIDS Research and Interventions (9 papers) and HIV/AIDS drug development and treatment (8 papers). Gary Sinclair is often cited by papers focused on HIV Research and Treatment (9 papers), HIV/AIDS Research and Interventions (9 papers) and HIV/AIDS drug development and treatment (8 papers). Gary Sinclair collaborates with scholars based in United States, Australia and United Kingdom. Gary Sinclair's co-authors include Sharon Weissman, Margaret A. Chesney, Amy C. Justice, Albert W. Wu, Susan E. Cohn, Linda Rabeneck, Robert Zackin, Judith L. Neidig, Allen L. Gifford and Cheryl Marcus and has published in prestigious journals such as New England Journal of Medicine, PLoS ONE and Clinical Infectious Diseases.

In The Last Decade

Gary Sinclair

19 papers receiving 896 citations

Hit Papers

Capsid Inhibition with Lenacapavir in Multidrug-Resistant... 2022 2026 2023 2024 2022 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection
    2022 164 citations Sorana Segal‐Maurer, Edwin DeJesus et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gary Sinclair United States 11 572 268 240 239 128 20 918
Anne K. Monroe United States 18 464 0.8× 136 0.5× 361 1.5× 276 1.2× 213 1.7× 73 1.0k
Abby Shevitz United States 18 636 1.1× 420 1.6× 181 0.8× 597 2.5× 58 0.5× 26 1.0k
Mieke H. Godfried Netherlands 17 320 0.6× 247 0.9× 232 1.0× 344 1.4× 333 2.6× 32 1.2k
Deborah S. Storm United States 17 692 1.2× 149 0.6× 220 0.9× 125 0.5× 394 3.1× 34 1.2k
María José Ferrer Spain 16 409 0.7× 271 1.0× 140 0.6× 181 0.8× 41 0.3× 42 1.0k
Mikaëla Smit United Kingdom 10 637 1.1× 239 0.9× 276 1.1× 685 2.9× 52 0.4× 20 1.0k
Mosepele Mosepele Botswana 16 373 0.7× 200 0.7× 170 0.7× 249 1.0× 77 0.6× 66 757
Carl Armon United States 21 921 1.6× 621 2.3× 425 1.8× 788 3.3× 119 0.9× 49 1.7k
Igho Ofotokun United States 17 624 1.1× 191 0.7× 315 1.3× 386 1.6× 261 2.0× 75 1.1k
Kevin Gough Canada 16 513 0.9× 156 0.6× 382 1.6× 125 0.5× 155 1.2× 43 1.0k

Countries citing papers authored by Gary Sinclair

Since Specialization
Citations

This map shows the geographic impact of Gary Sinclair's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary Sinclair with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary Sinclair more than expected).

Fields of papers citing papers by Gary Sinclair

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary Sinclair. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary Sinclair. The network helps show where Gary Sinclair may publish in the future.

Co-authorship network of co-authors of Gary Sinclair

This figure shows the co-authorship network connecting the top 25 collaborators of Gary Sinclair. A scholar is included among the top collaborators of Gary Sinclair based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary Sinclair. Gary Sinclair is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Colson, Amy E., Peter Ruane, Moti Ramgopal, et al.. (2025). 577. Week 48 Results of a Phase 2 Study Evaluating Once-weekly Oral Islatravir Plus Lenacapavir. Open Forum Infectious Diseases. 12(Supplement_1). 2 indexed citations
2.
Dandachi, Dima, Cindy Garris, David B. Richardson, et al.. (2025). Clinical Outcomes and Perspectives of People With Human Immunodeficiency Virus Type 1 Twelve Months After Initiation of Long-acting Cabotegravir and Rilpivirine in an Observational Real-world US Study (BEYOND). Open Forum Infectious Diseases. 12(5). ofaf220–ofaf220. 3 indexed citations
3.
4.
Karver, Tahilin Sanchez, Alessandro Berni, Antonella Castagna, et al.. (2023). Factors Associated with Health Care Providers' Preference for Forgoing an Oral Lead-In Phase When Initiating Long-Acting Injectable Cabotegravir and Rilpivirine in the SOLAR Clinical Trial. AIDS Patient Care and STDs. 37(1). 53–59. 5 indexed citations
5.
Sinclair, Gary, Michael Sension, Alexandra W. Dretler, et al.. (2023). 1607. Clinical Outcomes at Month 6 after Initiation of Cabotegravir and Rilpivirine Long-Acting (CAB + RPV LA) in an Observational Real-World Study (BEYOND). Open Forum Infectious Diseases. 10(Supplement_2). 5 indexed citations
6.
Ogbuagu, Onyema, Edwin DeJesus, Mezgebe Berhe, et al.. (2023). 1596. Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multi-Drug Resistant HIV: Week 104 Results. Open Forum Infectious Diseases. 10(Supplement_2). 4 indexed citations
7.
Sinclair, Gary, Samir K. Gupta, Ana M. Puga, et al.. (2022). 1288. US Healthcare Provider Perspectives on the initiation of cabotegravir and rilpivirine long-acting (CAB+RPV LA) in an observational real-world study (BEYOND). Open Forum Infectious Diseases. 9(Supplement_2). 2 indexed citations
8.
Czarnogorski, Maggie, Cindy Garris, Ronald D’Amico, et al.. (2022). Perspectives of healthcare providers on implementation of long‐acting cabotegravir plus rilpivirine in US healthcare settings from a Hybrid III Implementation‐effectiveness study (CUSTOMIZE). Journal of the International AIDS Society. 25(9). e26003–e26003. 20 indexed citations
9.
Segal‐Maurer, Sorana, Edwin DeJesus, Hans‐Jürgen Stellbrink, et al.. (2022). Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection. New England Journal of Medicine. 386(19). 1793–1803. 164 indexed citations breakdown →
10.
Garris, Cindy, Maggie Czarnogorski, Ronald D’Amico, et al.. (2022). Perspectives of people living with HIV‐1 on implementation of long‐acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation‐effectiveness study. Journal of the International AIDS Society. 25(9). e26006–e26006. 28 indexed citations
11.
12.
Burgess, Christopher, et al.. (2014). Strengthening Cardiovascular Disease Prevention in Remote Indigenous Communities in Australia's Northern Territory. Heart Lung and Circulation. 24(5). 450–457. 22 indexed citations
13.
Middleton, Paul M, et al.. (2010). Effectiveness of Morphine, Fentanyl, and Methoxyflurane in the Prehospital Setting. Prehospital Emergency Care. 14(4). 439–447. 69 indexed citations
14.
Kenealy, Timothy, et al.. (2007). Chronic Care Management evolves towards Integrated Care in Counties Manukau, New Zealand.. PubMed. 120(1252). U2489–U2489. 27 indexed citations
15.
Sinclair, Gary & Andrew Kerr. (2006). The Bold Promise Project: a system change in primary care to support cardiovascular risk screening.. PubMed. 119(1245). U2312–U2312. 25 indexed citations
16.
Justice, Amy C., et al.. (2001). Patient- and provider-reported adherence. Journal of Clinical Epidemiology. 54(12). S91–S98. 121 indexed citations
17.
Justice, Amy C., William C. Holmes, Allen L. Gifford, et al.. (2001). Development and validation of a self-completed HIV symptom index. Journal of Clinical Epidemiology. 54(12). S77–S90. 360 indexed citations
18.
Weissman, Sharon, Gary Sinclair, Cynthia L. Green, & William H. Fissell. (1999). Hydroxyurea‐Induced Hepatitis in Human Immunodeficiency Virus‐‐Positive Patients. Clinical Infectious Diseases. 29(1). 223–224. 9 indexed citations
19.
Sinclair, Gary, Peter W. Baas, & Steven R. Heidemann. (1988). Role of microtubules in the cytoplasmic compartmentation of neurons. II. Endocytosis in the growth cone and neurite shaft. Brain Research. 450(1-2). 60–68. 24 indexed citations
20.
Baas, Peter W., Gary Sinclair, & Steven R. Heidemann. (1987). Role of microtubules in the cytoplasmic compartmentation of neurons. Brain Research. 420(1). 73–81. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anne K. Monroe Breakdown of academic impact, for papers by Abby Shevitz Breakdown of academic impact, for papers by Mieke H. Godfried Breakdown of academic impact, for papers by Deborah S. Storm Breakdown of academic impact, for papers by María José Ferrer Breakdown of academic impact, for papers by Mikaëla Smit Breakdown of academic impact, for papers by Mosepele Mosepele Breakdown of academic impact, for papers by Carl Armon Breakdown of academic impact, for papers by Igho Ofotokun Breakdown of academic impact, for papers by Kevin Gough
Rankless by CCL
2026